Introduction
The membrane associated tyrosine kinase oncoprotein v-Src can transform a number of cell types and reduce the requirement for growth factors and anchorage which restrain normal cell growth. This suggests that vSrc alters the regulation of cyclin dependent kinases (CDKs) in response to inhibitory growth conditions. Work in a number of cell types has shown that v-Src increases the transcription of cyclin D1 (Aziz et al., 1999; Lee et al., 1999b; Sinibaldi et al., 2000) although expression of cyclin D1 in quiescent cells is not sucient to activate cyclin D1/CDK4/6 nor to induce S phase entry (Ladha et al., 1998; Resnitzky et al., 1994) . However, simultaneous expression of cyclin D1 and down regulation of the CDK inhibitor p27 induced NIH3T3 cells to enter S phase (Ladha et al., 1998) and we showed previously that p27 is down regulated in vSrc transformed Rat-1 ®broblasts (Johnson et al., 1998) .
The induction of cyclin D1 transcription by v-Src requires mitogen activated protein kinases (MAP kinases) and STAT3 (Aziz et al., 1999; Lee et al., 1999b; Sinibaldi et al., 2000) , but it is not known how v-Src represses p27 expression. In quiescent Ba/F3 cells p27 transcription is controlled by Forkhead transcription factor FKHR-L1 which is repressed by PI3-K in cells stimulated by IL-3 (Dijkers et al., 2000) . Since v-Src can substitute for IL-3 and activate PI3-K in Ba/F3 cells (Dijkers et al., 2000; Odajima et al., 2000) , it might also repress p27 transcription via activation of PI3-K.
The activities of two other kinases, cyclin E/CDK2 and cyclin A/CDK2 are required for S phase entry. The transcription of cyclins E and A in G 1 is repressed by retinoblastoma protein (pRb) (Botz et al., 1996; Le Cam et al., 1999; Schulze et al., 1995) and phosphorylation and inactivation of pRb by cyclin D1/CDK4/6 may be required for their expression. In addition cyclin D1/CDK4/6 sequesters p27 away from cyclin E/CDK2 complexes promoting their activation . Taken together, these ®ndings suggest that v-Src might induce S phase by simultaneously down regulating p27 and inducing cyclin D1 but it remains possible that v-Src directly aects other cell cycle proteins, such as pRb, cyclin E/CDK2 and cyclin A/CDK2.
To address this we examined changes in cell cycle proteins when S phase entry was induced by activating a temperature sensitive (ts) v-Src in quiescent Rat-1 cells. We found that v-Src sequentially up regulated cyclins D1, E and A and also down regulated p27 and activated cyclins D1/3/CDK4/6 and E/A/CDK2 at the G 1 to S phase transition. We examined whether down regulation of p27 was required for v-Src to activate cyclin/CDKs by engineering cells with inducible p27. To distinguish whether the increase in cyclin E or A expression was a direct consequence of activating v-Src or required cyclin D/CDK4/6 activity and pRb phosphorylation we engineered cells with inducible p16. Our results showed that both p27 and p16 inhibited activation of cyclin/CDKs and S phase entry by v-Src and that cyclin A expression but not cyclin E expression required cyclin D/CDK4/6 activity.
We showed previously v-Src activated both extracellular signalling regulated kinase (ERK) and PI3-K and that ERK was required for v-Src induced S phase in Rat-1 cells (Johnson et al., 2000; Wyke et al., 1995) . To address whether ERK or PI3-K are required for vSrc to increase the expression of cyclins D1 or E or to down regulate p27 we used pharmacological inhibitors of ERK activating kinase, MEK (U0126) or PI3-K (LY294002). We found that PI3-K was required for vSrc to increase MEK activity and that MEK was required for v-Src to increase expression of cyclins D1 and E. However, the MEK inhibitor prevented down regulation of p27 protein while the PI3-K inhibitor did not. We used the protease inhibitor N-acetyl-leucylleucyl-norleucinal (ALLN) to show that this was due to proteolytic degradation of p27 when PI3-K was inhibited.
Results

Activating v-Src in quiescent cells induces cyclins D1, E and A sequentially
Rat-1 cells expressing a temperature sensitive v-Src (ts LA 29 Rat-1) were grown at the restrictive temperature for several days, then made quiescent by incubating in medium containing 0.2% serum (low serum) for 48 h. We activated v-Src by shift to the permissive temperature and found as shown previously (Wyke et al., 1993) and in Figure 1a that cells entered S phase, beginning 16 h after activating v-Src, reaching a maximum of 35 ± 55% cells in S phase at 28 h.
Quiescent ts LA 29 Rat-1 cells expressed low levels of cyclins D1, D2 and D3 (Figure 1b , Cyclin D1 protein appeared as a doublet on immunoblots but the dierence between the two bands is not known.) Cyclin D1 protein and mRNA were up regulated within 8 h of activating v-Src. The mRNA increased up to sixfold (data not shown) whereas the protein increased only two-to threefold (Figure 1b) . In contrast, levels of cyclin D2 were only slightly higher after activating vSrc while the level of cyclin D3 protein fell (Figure 1b) . Activating v-Src had very little eect on the expression of CDK4 or CDK6 the D cyclin binding partners (Figure 1b) .
Cyclins E and A which regulate CDK2 activity, increased sequentially from very low levels after activating v-Src (Figure 1b ) with similar increases in the mRNA (data not shown). v-Src also increased the amount of a faster migrating form of CDK2 ( Figure  1b ) which was shown previously to be a form of CDK2 phosphorylated on T160 (Gu et al., 1992) . Immunoprecipitation of CDK2 from cell extracts and immunoblotting with antibodies speci®c for phospho-T160 CDK2 con®rmed that the lower band was phosphorylated on T160 (Figure 1c ) and that cyclin E coimmunoprecipitated only the phosphorylated CDK2 (Figure 1c ). Thus activating v-Src sequentially up regulated cyclins D1, E and A and increased the expression of CDK2 phosphorylated on T160.
Since v-Src increased the expression of cyclins and phospho-T160 CDK2 we checked whether this correlated with activation of CDKs by examining the phosphorylation of pRB family members (the best characterized in vivo substrate for CDKs) and by in vitro kinase assays. Activating v-Src induced hyperphosphorylation of pRb (shown by a decrease in its mobility on SDS ± PAGE, Figure 2a ) concurrently with an increase in the activity associated with cyclins D1, D3, E and A ( Figure 2b ) and S phase entry.
The timing of CDK activation correlated with p27 down regulation Increasing the expression of either cyclin D1 or cyclin E in quiescent cells, using cell lines with isopropyl-b-Dthiogalactopyranoside (IPTG) inducible cyclin D1 or cyclin E, did not activate the associated kinases (data not shown) consistent with published results (Resnitzky et al., 1994) . Therefore we examined other factors which in¯uence CDK activity.
CDK activity is also controlled by the binding of inhibitory subunits; p15, p16, p18 and p19 bind and inhibit CDK4 and CDK6 while p21, p27 and p57 bind to all four cyclin/CDK complexes. We could not detect p21, p57, p15, p16 or p19 expression by immunoblotting and expression of p18 was not aected by v-Src (data not shown). Lack of p21 expression is consistent with published data showing that the p21 promoter is methylated in Rat-1 cells (Allan et al., 2000) . In contrast, p27 decreased from 16 h (Figure 3a ) consistent with it with having a role in regulating CDK activity. Therefore we examined whether there was a decrease in p27 in cyclin/CDK complexes when they were activated. We immunoprecipitated cyclins D1, D3 and E and immunoblotted with antibodies to p27 and CDKs 2, 4 and 6. The increase in cyclin D1 expression was accompanied by an increase in the amount of cyclin D1/CDK4/6/p27 complexes but the composition of the cyclin D1/CDK4/6/p27 and cyclin D3/CDK4/6/ p27 complexes changed very little when they were activated (Figure 3b ). In contrast, the activation of cyclin E/CDK2 correlated with an increase in cyclin E expression and its association with more CDK2 (Figure 3c ). There was no simultaneous increase in the amount of p27 which coimmunoprecipitated with cyclin E (Figure 3c ) suggesting that the ratio of p27 to cyclin E/CDK2 was lower in the active complexes.
P27 over expression inhibited v-Src induced activation of CDKs and S phase entry
To investigate whether the decrease in p27 induced by v-Src was required to activate cyclin/CDK complexes we made several cell lines with IPTG inducible p27 ( Figure 4a ) and found that p27 expression inhibited Sphase entry ( Figure 4b ). The greatest inhibition of S phase correlated with the highest level of p27. We used the line with highest p27 expression (K13) and found that p27 over expression prevented activation of cyclin D1/CDK4/6 and reduced activation of cyclin D3/CDK4/6 (Figure 4c ). Therefore p27 down regulation was required for v-Src to activate cyclin D1/D3/ CDK4/6. Over expression of p27 increased the expression cyclins D1 and D3 ( Figure 4d ) and their association with CDKs 2, 4 and 6 (Figure 4e,f), consistent with the role of p27 as an assembly factor for D cyclins (Cheng et al., 1999) . p27 over expression also prevented activation of cyclin E/CDK2 (Figure 4c ), cyclin A/CDK2 (data not shown) and cyclin A expression ( Figure 4d ). As for the D cyclins, p27 did not prevent cyclin E/CDK2 activation by reducing cyclin E expression ( Figure 4d ) but increased the amount of p27 associated with cyclin E/CDK2 (Figure 4g ). p27 over expression had no eect on the amount of phospho-T160 CDK2 associated with cyclin E (Figure 4g ) suggesting that p27 did not prevent cyclin E/CDK2 activation by inhibiting CDK2 phosphorylation. CDK2 is phosphorylated on T160 by CDK activating kinase (CAK). Phosphorylation of CDK2 by CAK is required for CDK2 activation and is thought to be regulated either by p27, which prevents CAK from accessing CDK2 (Aprelikova et al., 1995) or by binding of cyclins which prevent dephosphorylation (Poon and Hunter, 1995) . We used cells engineered with IPTG inducible cyclin E (Johnson et al., 1998) to over-express cyclin E in quiescent cells and found that it associated with more phospho-T160 CDK2 (Figure 4h ). Despite the increase in associated (c) Cyclins D1, D3 or E were immunoprecipitated from cell extracts and subject to in vitro kinase assays using pRb-C as substrate then immunoblotted with antibodies to phospho-Ser 795 pRb. (d) Cell extracts were immunoblotted with antibodies to cyclins D1, D3, E or A. (e) Cyclin D1 was immunoprecipitated from cell extracts and immunoblotted with antibodies speci®c for cyclin D1, p27, CDK4, CDK6, or CDK2. (f) Cyclin D3 was immunoprecipitated from cell extracts and immunoblotted with antibodies speci®c for cyclin D3, p27, CDK4, or CDK6. (g) Cyclin E was immunoprecipitated from cell extracts and immunoblotted with antibodies speci®c for cyclin E, p27, CDK2 or phospho-T160 CDK2. (h) Quiescent cells engineered with IPTG inducible cyclin E were harvested 24 h after addition of IPTG. Cyclin E was immunoprecipitated from cell extracts then immunoblotted with antibodies to cyclin E, CDK2, phospho-T160 CDK2 or p27
Cell cycle regulation by v-Src D Riley et al phospho-T160 CDK2 the kinase was inactive (data not shown), probably as a result of the large increase in associated p27 (Figure 4h ). Thus the increase in CDK2 phosphorylation induced by v-Src is probably due to increased cyclin E expression but is not sucient to activate cyclin E associated kinase activity nor to promote degradation of associated p27.
CDK activity was required for v-Src induced expression of cyclin A but not for cyclin E elevation or p27 down regulation Cyclin D/CDK4/6 activity controls cyclin E expression by phosphorylating pRb which releases pRb from the E2F complex and relieves repression of the cyclin E promoter (Harbour et al., 1999) . In addition, cyclin E/ CDK2 is thought to regulate the expression of p27 by phosphorylating it and promoting its ubiquitin dependent degradation (Montagnoli et al., 1999) . To investigate the role of cyclin D/CDK4/6 activity in the expression of cyclin E and the role of cyclin E/ CDK2 activity in the regulation of p27 levels we engineered cells with IPTG inducible p16. p16 binds and inhibits CDKs 4 and 6 but also inhibits cyclin E/ CDK2 indirectly (McConnell et al., 1999) . We isolated a number of clones with dierent levels of p16 expression and found that p16 induction prevented S phase entry (one clone shown in Figure 5a ,b). Figure  5c shows that p16 did indeed prevent activation of cyclin D1/CDK4/6, cyclin D3/CDK4/6, cyclin E/ CDK2 and cyclin A/CDK2 by v-Src. Activating v-Src increased cyclin E expression and down regulated p27 independent of CDK activity and cell cycle progression whereas CDK activity was required for v-Src to increase cyclin A expression (Figure 5d ). To determine how p16 prevented cyclin D1/CDK4 and cyclin E/CDK2 activation we examined the composition of cyclin/CDK complexes. p16 increased the amount of p27 and decreased the amount of phospho-T160 CDK2 associated with cyclin E (Figure  5e ). P16 also increased the amount of p27 and the slower migrating form of CDK2 associated with cyclin D1 (Figure 5f ). p16 did not reduce the association of cyclin D1 with CDK4 but instead coimmunoprecipitated with cyclin D1 (Figure 5f ), suggesting that it was able to form ternary complexes with cyclin D1/CDK4. p16 had no eect on the cyclin D3 complexes (data not shown). We conclude that p16 probably prevented the activation of cyclin D1/CDK4 and cyclin E/CDK2 by increasing their association with p27, decreasing the association of cyclin E with phospho-T160 CDK2, increasing the association of cyclin D1 with inactive CDK2 and by binding to cyclin D1/CDK4.
MEK and PI3-K mediate the effects of v-Src on cyclins D1, E and p27
We showed previously that activating v-Src in quiescent Rat-1 cells increased ERK activity (Wyke et al., 1995) and that v-Src binds and activates PI3-K (Haefner et al., 1995; Johnson et al., 2000) . Blocking ERK activation or PI3-K prevented v-Src induced mitogenesis (Aziz et al., 1999; Odajima et al., 2000; Wyke et al., 1995) . To examine the roles of these two kinases in v-Src induced S phase entry and expression of cyclins D1, D3, E and p27 we added pharmacological inhibitors of the upstream ERK activator, MEK (U0126) (Davies et al., 2000; Duncia et al., 1998; Favata et al., 1998) , or PI3-K (LY294002) (Vlahos et al., 1994) 8 h after activating v-Src. We immunoblotted cell extracts with antibodies against phospho-ERK or phospho-AKT (which binds the lipid products of PI3-K and becomes phosphorylated). Figure 6a shows that 8 h after activating v-Src there was an increase in phosphorylated ERK and AKT and that adding U0126 reduced ERK phosphorylation while adding LY294002 reduced AKT phosphorylation. Inactivating v-Src reduced both ERK and AKT phosphorylation (Figure 6a, Src o) . LY294002 also reduced ERK phosphorylation suggesting that PI3-K activity is required for v-Src to activate MEK. We compared the eect of these treatments on S phase entry by BrdU labelling and¯ow cytometry and found that inactivating v-Src or adding U0126 or LY294002 at 8 h inhibited S phase by 71, 79 or 83% respectively.
Since both U0126 and LY294002 prevented MEK activation they may block v-Src induced mitogenesis by a similar mechanism, alternatively LY294002 may have additional eects mediated by PI3-K alone. We added U0126 or LY294002 at 8 h and examined the activities associated with cyclins D1, D3, E, and A by in vitro kinase assays (Figure 6b ) or the phosphorylation of pRb (Figure 6c ) and found that both inhibitors prevented activation of CDKs by v-Src. Both inhibitors also prevented the increase in expression of cyclins D1 and E (Figure 6c ) but did not prevent the small decrease in p27 mRNA induced by v-Src (Figure 6d ). In contrast U0126 prevented the v-Src induced decrease in p27 protein expression (Figure 6c ) suggesting that blocking MEK prevented down regulation of p27 protein not mRNA. Adding LY294002 did not prevent down regulation of p27 protein and reduced cyclin D3 expression (Figure 6c ). We found previously that blocking PI3-K induced v-Src transformed cells growing in low serum conditions to undergo apoptosis and that p27 was cleaved by caspases (Johnson et al., 2000) . However, we could not detect the caspase cleavage product of p27 in quiescent cells treated with LY294002 and the decrease in p27 and cyclins D1 and D3 induced by LY294002 was not prevented by adding the caspase inhibitor ZVAD (data not shown). In contrast, adding the protease inhibitor ALLN to LY294002 treated cells prevented the decrease in cyclins D1, D3 and p27 (Figure 6e ) suggesting that blocking PI3-K promoted caspase independent proteolysis of D cyclins and p27.
Discussion
In order to understand the mechanism of cell cycle regulation by v-Src we investigated whether v-Src Oncogene Cell cycle regulation by v-Src D Riley et al directly aected the expression of cell cycle regulators other than cyclin D1, previously shown to be induced by v-Src in several dierent cell types (Aziz et al., 1999; Lee et al., 1999b; Sinibaldi et al., 2000) and p27, which we showed was down regulated in v-Src transformed cells (Johnson et al., 1998) . We also investigated whether p27 down regulation was required to activate cyclin/CDKs and the roles of PI3-K and MEK in mediating the eects of v-Src. The per cent cells in S phase was determined by BrdU labelling and¯ow cytometry. (c) Cyclins D1, D3, E and A were immunoprecipitated from cell extracts and subject to in vitro kinase assays using pRb-C as substrate then immunoblotted with antibodies to phospho-Ser 795 pRb. (d) Cell extracts were immunoblotted with antibodies to cyclins E, A or p27. (e) Cyclin E was immunoprecipitated from cell extracts and immunoblotted with antibodies speci®c for cyclin E, p27, CDK2 or phospho-T160 CDK2. (f) Cyclin D1 was immunoprecipitated from cell extracts and immunoblotted with antibodies speci®c for cyclin D1, p27, CDK2, CDK4 or p16
The role of p27 down regulation in the activation of cyclins D1/D3/CDK4/6, cyclin E/CDK2 and cyclin A/CDK2 p27 down regulation by v-Src mediated the activation of cyclins D1/D3/CDK4/6, cyclin E/CDK2 and cyclin A/CDK2. No detectable changes in D cyclin complexes accompanied their activation by v-Src but inactive complexes, formed when either p27 or p16 were over expressed, contained more p27 and inactive CDK2 (Figures 4e and 5f ) similar to complexes found in senescent cells expressing high levels of p16 (Morisaki et al., 1999) . Although p21/p27 family members are essential assembly factors for D cyclins with CDKs (Cheng et al., 1999; LaBaer et al., 1997) , they also inhibit cyclin D1/D3/CDK4/6 when present in higher ratios (Blain et al., 1997; Fotedar et al., 1996; Harper et al., 1995; LaBaer et al., 1997) . Therefore the increased association of p27 with cyclin D1/D3/ CDK4/6 probably contributed to their inactivation.
In cells over-expressing p16, p16 was present in cyclin D1 immunoprecipitates (Figure 5f ) suggesting that it inhibited cyclin D1/CDK4/6 by forming ternary complexes. Although p16 family members bind to CDK4/6 and not to cyclins (Guan et al., 1994; Hall et al., 1995; Hirai et al., 1995) and can inhibit cyclin D/ CDK4/6 by preventing the assembly of D cyclins with CDK4/6 or by displacing D cyclins from CDK4/6 (Hirai et al., 1995; Sandhu et al., 1997) , both p15 and p19 have been found in inactive cyclin D/CDK4/6 complexes in vitro (Hirai et al., 1995) and in vivo (Adachi et al., 1997; Reynisdottir and Massague, 1997) .
v-Src activated cyclin E/CDK2 by increasing the amount of cyclin E and phospho-T160 CDK2 and down regulating p27 since active complexes had a lower ratio of p27 to cyclin E/CDK2 (Figure 3b ). p27 down regulation limited the amount of p27 in the complex but was not required for CAK to phosphorylate and activate CDK2 (Figure 4g ) as has been suggested (Aprelikova et al., 1995) . Instead v-Src probably increased the phosphorylation of CDK2 on T160 by increasing the amount of cyclin E expressed (Figure 4h) . v-Src activated cyclin A/CDK2 by increasing the amount of cyclin A expressed. v-Src was unable to Figure 6 The eect of v-Src, U0126 or LY294002 on AKT or ERK phosphorylation, CDK activity and levels of cyclins or p27. Quiescent cells were induced to enter S phase by activating v-Src. (a) 8 h after activating v-Src it was inactivated (Src o) or U0126 or LY294002 were added and cells were harvested 1 h later. Cell extracts were immunoblotted with antibodies speci®c for phospho-T202/Y204 ERK, total ERK, phospho-S473 AKT or total AKT. (b to e) 8 h after activating v-Src it was inactivated (Src o) or U0126, LY294002 (b to d) or LY294002 plus ALLN (e) were added and cells were harvested 16 h later (24 h after activating v-Src) (Q ± quiescent cells, C ± control cells harvested 24 h after activating v-Src). (b) Extracts from cells were immunoprecipitated with antibodies speci®c for cyclins D1, D3, E or A or rabbit IgG (IgG) then subjected to in vitro kinase assays using histone H1 or pRb-C as a substrate. Kinase activity was detected by autoradiography or antibodies speci®c for phospho-S795 pRb. (c) Proteins extracted from cells were analysed by immunoblotting using antibodies speci®c for pRb, cyclins D1, D3 or E, or p27. (d) RNA extracted from cells was analysed by Northern blotting, hybridized with a p27 cDNA probe and p27 mRNA levels were quantitated by phosphorimaging. We monitored for loading by staining the RNA gel with ethidium bromide, photographing it under UV light and quantitating the 18S and 28S rRNA. Histogram shows the p27 expression levels in phosphorimager units corrected for loading. (e) Proteins extracted from cells were analysed by immunoblotting using antibodies speci®c for cyclins D1, D3 or p27 increase cyclin A expression when CDK activity was blocked by exogenous p27 or p16 suggesting that the eect of v-Src on cyclin A was mediated by pRb family members.
Regulation of D cyclins by v-Src
v-Src increased cyclin D1 expression via activation of PI3-K and MEK, consistent with the requirement for ERK to increase cyclin D1 transcription (Lee et al., 1999b) and PI3-K to prevent cyclin D1 degradation (Diehl et al., 1998) . v-Src decreased cyclin D3 expression and this was reversed by arti®cial over expression of p27. p27 is an assembly factor for D cyclins (Cheng et al., 1999) and the decrease in cyclin D3 expression may result from its inability to assemble with CDK4 due to down regulation of p27 by v-Src. PI3-K activity also reduced cyclin D3 and p27 degradation. Examining the sequence of D cyclins revealed that all three contain the GSK-3b phosphorylation site which controls the degradation of cyclin D1 (Lee et al., 1999b) suggesting that v-Src prevented the degradation of cyclin D1/D3/CDK4/6/p27 complexes by activating PI3-K.
Regulation of cyclin E/CDK2 by v-Src
v-Src increased cyclin E levels after it increased cyclin D1 levels but the increase in cyclin E did not require CDK activity (Figures 4d and 5d) suggesting that the eect of v-Src on cyclin E is not mediated through the pRb and E2F via E2F sites in the cyclin E promoter (Botz et al., 1996; Hurford et al., 1997; Le Cam et al., 1999) . Consistent with this v-Src activated cyclin D1/ D3/CDK4/6 and cyclin E/A/CDK2 simultaneously, not sequentially. However, over expression of p16, which binds to CDKs 4 and 6 and not CDK2, prevented cyclin E/CDK2 activation. Over expression of p16 inactivated cyclin E/CDK2 by redistributing p27 to cyclin E/CDK2 complexes and reducing CDK2 phosphorylation by CAK but to investigate whether these eects are mediated through binding to CDK4 and 6 it will be necessary to express p16 in cells expressing mutant CDKs 4 and 6 which cannot be inhibited by p16. Alternatively, p16 might directly aect CDK2 phosphorylation by blocking CAK activity. p16 binds to CAK but does not prevent it from phosphorylating CDK2 (Nishiwaki et al., 2000) . Activation of S. cerevisiae CAK (Cak1) requires the chaperone Cdc37 (Farrell and Morgan, 2000) and in S. pombe, Cak1 activates CAK (Lee et al., 1999a ). An enzyme similar to S. cerevisiae Cak1 has been identi®ed in mammalian cells (Kaldis and Solomon, 2000) therefore p16 may inhibit CAK by preventing the association of mammalian Cak1 with Cdc37 analogous to the way it inhibits CDK4 association with Cdc37.
Both MEK and PI3-K activity were required for vSrc to increase cyclin E expression (Figure 6c ) but further work is needed to determine whether they aect cyclin E mRNA or protein.
Regulation of p27 by v-Src
Activating v-Src down regulated p27 mRNA ( (Johnson et al., 1998) and Figure 6d ) and protein ( Figure 3a ) by 2 ± 3-fold suggesting that p27 expression was controlled at least partly at the mRNA level. v-Src probably did not control p27 mRNA by repressing Forkhead transcription factors which promote p27 transcription in Ba/F3 cells and are inhibited by PI3-K (Dijkers et al., 2000) because PI3-K activity was not required for v-Src to down regulate p27 mRNA (Figure 6d ). v-Src also down regulated p27 in the absence of cyclin E/ CDK2 activity, shown previously to be required for p27 degradation (Montagnoli et al., 1999) (Figure 5d ). However down regulation of p27 protein but not mRNA required MEK activity (Figure 6c,d ) possibly because p27 must be phosphorylated by ERK (Alessandrini et al., 1997) before it is degraded.
Conclusions
We propose a mechanism for v-Src induced cell cycle progression in Rat-1 cells, which extends previous observations on the roles of cyclin D1 and p27, integrates these with novel ®ndings in this paper and delineates issues for further study. v-Src increased cyclin D1 levels by activating MEK in a PI3-K dependent manner, whilst PI3-K independently reduced proteolysis of cyclins D1 and D3. Activation of PI3-K and MEK also mediated cyclin E expression, by a mechanism yet to be de®ned which is independent of CDK activation. This, in turn, increased the phosphorylation of CDK2 on T160. v-Src down regulated p27 partly by decreasing p27 mRNA by a PI3-K and MEK independent mechanism and partly by MEK dependent proteolysis of p27. The molecular basis for p27 mRNA down regulation or p27 proteolysis has yet to be determined, although v-Src induced calpain activation (Carragher et al., submitted) remains a candidate. p27 down regulation was required for activation of cyclins D1/D3/ CDK4/6 and cyclin E/A/CDK2. Cyclin E/CDK2 and/or cyclin D1/D3/CDK4/6 phosphorylated pRb family members and this was required for cyclin A expression at the G 1 to S phase transition. In summary, v-Src modi®es levels of both positive and negative regulators of cell cycle progression, its direct eects on cyclin E and p27 explaining our previous demonstration that v-Src and ERK activity is needed throughout G 1 for successful entry of quiescent cells into S phase (Wyke et al., 1995) .
Materials and methods
Cell culture ts LA 29 Rat-1 cells (White and Weber, 1988) were cultured as described previously (Johnson et al., 1998) . To induce quiescence 5 to 10610 5 cells per 9 cm plate or 2.5 to 5610 6 cells per 15 cm plate were seeded at the permissive temperature (358C). After 24 h they were fed, shifted to the restrictive temperature (39.58C) and grown for 3 days. The
Cell cycle regulation by v-Src D Riley et al medium was then replaced with medium containing 0.2% serum (low serum) for 48 h. Cells were induced to enter S phase by shift to 358C then harvested at intervals thereafter.
BrdU immunostaining, propidium iodide staining and flow cytometry
As described previously (Johnson et al., 1998) .
Generation of IPTG inducible p27-or p16-expressing cell lines using the Lac-Switch TM inducible expression system
The plasmid pOPRSVp27 was generated by cloning a 1.2 kb BamHI ± BglII fragment containing the coding region and some 3' untranslated region of human p27 cDNA (gift from S Coats, Amgen, CA, USA) into a modi®ed pOPRSVICAT vector (Stratagene) containing a BclII site in place of the CAT gene. The plasmid pOPRSVp16 was a gift from Gordon Peters, (ICRF, London). 5 mg plasmid containing p27 or p16 was co-transfected with 5 mg p3'SS Lac repressor plasmid (Stratagene) into ts LA29 Rat-1 cells in a 60 mm plate using DOTAP (Boehringer Mannheim). Clones were selected with 650 mg/ml active G418 and 200 mg/ml hygromycin B at 358C and screened for the ability to express p16 or p27 proteins following addition of 1 mM IPTG to the culture medium. The clones were maintained in medium containing 200 mg/ml hygromycin B and 650 mg/ml active G418 at 358C or half these drug concentrations at 39.58C.
Immunoblotting
Immunoblotting was carried out as described previously (Johnson et al., 1998) .
Northern blotting
Northern blotting was carried out as described previously (Johnson et al., 1998) except that RNA was extracted using RNeasy (Quiagen) and the probe was a 2.2 kb EcoRI fragment containing the entire human p27 cDNA (gift of S Coats, Amgen, CA, USA). p27 mRNA levels were quantitated by phosphorimaging.
Protein lysates
Cells were rinsed twice in ice cold PBS, tilted on ice for 10 min to drain and remaining PBS removed. Plates were stored at 7708C. Cells were thawed then lysed in cell lysis buer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 0.1% Tween-20, 10% glycerol, 1 mM NaF, 10 mg/ml leupeptin, 20 u/ml aprotinin, 10 mM bglycerophosphate, 0.1 mM Na orthovanadate, 0.1 mM PMSF) to give a protein concentration of approximately 1 mg/ml. They were scraped into a microcentrifuge tube then sonicated on ice for 3610 s with 10 s between each. They were spun at 14 000 r.p.m. for 5 mins at 48C, the supernatant was removed and protein concentration measured using Coomassie protein assay reagent (Pierce, Cat #23200). Aliquots of 200 mg to 500 mg protein were made up to 0.5 ml then snap frozen on dry ice and stored at 7708C.
Immunoprecipitations and kinase reactions
Protein-A sepharose (Sigma P-3391) was pre-swollen in PBS, washed 36 in PBS and 36 in lysis buer. Protein extracts were pre-cleared at 48C for 1 h with 25 ml 50% protein A sepharose beads or 5 ml Rabbit IgG agarose (Sigma A2909). They were spun for 10 s in a microfuge, and the supernatants transferred to new tube containing 0.5 mg antibody solution or 5 ml of antibody coupled to agarose beads. They were placed on rollers at 48C for 1 h then 12.5 ml 50% slurry protein A-sepharose was added to each tube. For mouse primaries protein A sepharose was pre-bound to rabbit antimouse IgG (Sigma M-7023) (1 : 10 volume) for 1 h. They were placed on rollers at 48C for a further 1 h then Spun for 10 s in a microfuge. Sepharose CL 4B (CL-4B-200 Sigma) was added as carrier and the beads were washed 36 with 1 ml ice cold lysis buer then twice with 1 ml ice cold kinase buer without ATP or substrate (Kinase buer: 50 mM HEPES pH 7.5, 50 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 1 mM ATP (cold assays) or 50 mM ATP plus 10 mCi g 32 P-ATP (hot assays), GST-pRb-C 763 ± 928 0.5 ± 2.5 mg per reaction (cold assays) or histone H1 1 mg per reaction (hot assays). (Bacteria expressing GST-pRb-C; kind gift of Sybille Mittnacht ICR, London). After ®nal wash, all supernatant was removed and 20 ml kinase buer containing ATP and substrate was added. Assays were vortexed gently and incubated at 308C for 30 mins, mixing intermittently. Reactions were stopped by adding 30 ml 26SDS loading buer and boiling for 10 mins. They were separated by SDS ± PAGE and either exposed to ®lm or immunoblotted with antibodies speci®c for phospho-S795 pRb as described by the manufacturer. The primary antibodies were detected with protein A-HRP (1 : 5000) (NA 9120, Amersham), anti rabbit IgG-HRP (Cell Signaling Technology #7071-1) or antimouse IgG-HRP (CST #7072-1) and enhanced chemiluminescence (ECL, RPN 2106, Amersham).
Antibodies
